Bridge Pharma, Inc.

United States of America

Back to Profile

1-32 of 32 for Bridge Pharma, Inc. Sort by
Query
Aggregations
Jurisdiction
        World 17
        United States 10
        Canada 5
Date
2023 1
2021 4
2020 3
Before 2020 24
IPC Class
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen 19
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine 12
A61K 9/00 - Medicinal preparations characterised by special physical form 10
A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings 8
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca 4
See more
Status
Pending 1
Registered / In Force 31
Found results for  patents

1.

TREATMENT OF DERMAL CYTOKINE STORM SYNDROMES

      
Application Number US2022035228
Publication Number 2023/278381
Status In Force
Filing Date 2022-06-28
Publication Date 2023-01-05
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Pucaj, Kresimir

Abstract

Described herein are methods of treating human and canine patients suffering from dermal Cytokine Storm syndromes related to dermal diseases such as atopic dermatitis, psoriasis or urticaria. A method of reducing the incidence and/or the intensity of a symptom of dermal hypercytokinemia in a patient suffering from an underlying dermal condition who develops the dermal hypercytokinemia as a consequence of the underlying dermal condition includes administering to the patient a therapeutically effective amount of norketotifen an isomer, an isomeric mixture, a prodrug or a pharmaceutically acceptable salt thereof. The symptom of dermal hypercytokinemia is an eruption of new dermal lesions accompanied by intense lesional and / or non-lesional pruritus.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 9/20 - Pills, lozenges or tablets
  • A61P 11/00 - Drugs for disorders of the respiratory system
  • A61P 31/12 - Antivirals
  • A61P 17/00 - Drugs for dermatological disorders

2.

METHODS OF TREATMENT OF INFLAMMATORY CYTOKINE-RELATED ARTHRITIC DISORDERS

      
Application Number US2021019509
Publication Number 2021/173744
Status In Force
Filing Date 2021-02-25
Publication Date 2021-09-02
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.
  • Pucaj, Kresimir

Abstract

Methods of treating a patient suffering from a TNFα associated arthritic disorder with the cytokine release inhibitor norketotifen include orally or topically administering to the subject in need thereof a therapeutically effective amount of norketotifen, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof. Also included are methods of intra-articular injection of norketotifen, such as into a joint of a subject in need thereof.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

3.

METHODS OF TREATMENT OF ASTHMA AND COPD

      
Document Number 03168125
Status Pending
Filing Date 2020-07-30
Open to Public Date 2021-07-29
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.
  • Pucaj, Kresimir

Abstract

Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respirator}'- disorders such as CQPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune·· suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

4.

METHODS OF TREATMENT OF ASTHMA AND COPD

      
Application Number US2020044167
Publication Number 2021/150268
Status In Force
Filing Date 2020-07-30
Publication Date 2021-07-29
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.
  • Pucaj, Kresimir

Abstract

Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respirator}'- disorders such as CQPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune·· suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

5.

Methods of treatment of asthma and COPD

      
Application Number 17177888
Grant Number 11197851
Status In Force
Filing Date 2021-02-17
First Publication Date 2021-06-24
Grant Date 2021-12-14
Owner BRIDGE PHARMA INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.
  • Pucaj, Kresimir

Abstract

Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.

IPC Classes  ?

  • A61K 31/4465 - Non-condensed piperidines, e.g. piperocaine only substituted in position 4
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 11/06 - Antiasthmatics
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

6.

Methods of treatment of asthma and COPD

      
Application Number 16943426
Grant Number 10959992
Status In Force
Filing Date 2020-07-30
First Publication Date 2020-11-12
Grant Date 2021-03-30
Owner BRIDGE PHARMA INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.
  • Pucaj, Kresimir

Abstract

Described herein are methods of administering the non-steroidal anti-inflammatory drug norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorders such as COPD and asthma to human patient in need of such treatment, without exposing said patient to adverse immune-suppressive effects. Methods include treating acute and potentially life-threatening exacerbations of COPD and asthma with norketotifen.

IPC Classes  ?

  • A61K 31/4465 - Non-condensed piperidines, e.g. piperocaine only substituted in position 4
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 11/06 - Antiasthmatics
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

7.

METHODS OF TREATMENT OF RESPIRATORY DISORDERS

      
Document Number 03131137
Status In Force
Filing Date 2020-02-14
Open to Public Date 2020-08-27
Grant Date 2024-05-28
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.
  • Pucaj, Kresimir

Abstract

Described herein are methods of administering the anti-inflammatory drug norketotifen, an isomer, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorder such as asthma and COPD in a human patient in need of such treatment, without exposing said patient to adverse immune-suppression. Dosage regimens for oral administration including a loading dosage followed by a maintenance dosage are described. Also described are methods and conditions wherein norketotifen is administered by oral inhalation. Yet, further included are methods of administering norketotifen directly to the nasal passages of the human patients in need thereof, in order to reduce or eliminate inflammatory symptoms of airways disorders, such as sinusitis, laryngitis, nasopharyngitis and various forms of rhinitis.

IPC Classes  ?

  • A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61P 11/00 - Drugs for disorders of the respiratory system
  • A61P 11/06 - Antiasthmatics

8.

METHODS OF TREATMENT OF RESPIRATORY DISORDERS

      
Application Number US2020018205
Publication Number 2020/172047
Status In Force
Filing Date 2020-02-14
Publication Date 2020-08-27
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent, B.
  • Pucaj, Kresimir

Abstract

Described herein are methods of administering the anti-inflammatory drug norketotifen, an isomer, a prodrug, or a pharmaceutically acceptable salt thereof for the treatment of a respiratory disorder such as asthma and COPD in a human patient in need of such treatment, without exposing said patient to adverse immune-suppression. Dosage regimens for oral administration including a loading dosage followed by a maintenance dosage are described. Also described are methods and conditions wherein norketotifen is administered by oral inhalation. Yet, further included are methods of administering norketotifen directly to the nasal passages of the human patients in need thereof, in order to reduce or eliminate inflammatory symptoms of airways disorders, such as sinusitis, laryngitis, nasopharyngitis and various forms of rhinitis.

IPC Classes  ?

9.

Formulations and methods for treating high intraocular pressure

      
Application Number 15071819
Grant Number 09694003
Status In Force
Filing Date 2016-03-16
First Publication Date 2017-04-20
Grant Date 2017-07-04
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.
  • Johnson, Keith

Abstract

Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt % to about 1.0 wt % norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving. Also included herein is a method of treating a human in need of a reduction in intraocular pressure by administering an intranasal formulation that includes a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the human in need thereof. Also, the beneficial effects of known drugs for high IOP are improved by co-administration with norketotifen.

IPC Classes  ?

  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 9/06 - OintmentsBases therefor
  • A61K 9/107 - Emulsions

10.

FORMULATIONS AND METHODS FOR TREATING HIGH INTRAOCULAR PRESSURE

      
Application Number US2016055404
Publication Number 2017/066052
Status In Force
Filing Date 2016-10-05
Publication Date 2017-04-20
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.
  • Johnson, Keith

Abstract

Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt% to about 1.0 wt% norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving. Also included herein is a method of treating a human in need of a reduction in intraocular pressure by administering an intranasal formulation that includes a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the human in need thereof. Also, the beneficial effects of known drugs for high IOP are improved by co-administration with norketotifen.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 27/06 - Antiglaucoma agents or miotics

11.

METHODS OF TREATMENT OF NON-HISTAMINIC PRURITUS IN MAMMALS

      
Application Number US2016033177
Publication Number 2016/200578
Status In Force
Filing Date 2016-05-19
Publication Date 2016-12-15
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen, an isomer, or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with a dermal disorder, a nerve disorder, or a systemic disorder.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61P 17/04 - Antipruritics

12.

METHODS OF TREATMENT OF NON-HISTAMINIC PRURITUS IN MAMMALS

      
Document Number 02988564
Status In Force
Filing Date 2016-05-19
Open to Public Date 2016-12-15
Grant Date 2021-10-05
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen, an isomer, or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with a dermal disorder, a nerve disorder, or a systemic disorder.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61P 17/04 - Antipruritics

13.

Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients

      
Application Number 15134807
Grant Number 09439895
Status In Force
Filing Date 2016-04-21
First Publication Date 2016-08-11
Grant Date 2016-09-13
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.

Abstract

Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with diabetes.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 9/00 - Medicinal preparations characterised by special physical form

14.

Medicinal treatment of dermal infectious disorders with norketotifen

      
Application Number 15071546
Grant Number 09808419
Status In Force
Filing Date 2016-03-16
First Publication Date 2016-07-07
Grant Date 2017-11-07
Owner BRIDGE PHARMA, INC (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of dermal infectious disorders, in human patients, by administering a therapeutically effective amount of RS-norketotifen.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/06 - OintmentsBases therefor
  • A61K 9/10 - DispersionsEmulsions
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
  • A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 47/02 - Inorganic compounds
  • A61K 9/107 - Emulsions
  • A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
  • A61K 9/20 - Pills, lozenges or tablets

15.

Methods of treatment of histamine H-4 receptor-related pruritus associated with nerve disorders

      
Application Number 14820831
Grant Number 09333199
Status In Force
Filing Date 2015-08-07
First Publication Date 2015-12-03
Grant Date 2016-05-10
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of histamine H-4-related pruritus associated with nerve disorders, by administering a combined histamine H-1 and H-4 receptor inhibitor, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 9/00 - Medicinal preparations characterised by special physical form

16.

Methods of treatment of non-histaminic pruritus

      
Application Number 14736626
Grant Number 09345697
Status In Force
Filing Date 2015-06-11
First Publication Date 2015-10-01
Grant Date 2016-05-24
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of RS-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine H-1-, H-2- and H-4-receptor inhibitors. In certain aspects, the non-histaminergic pruritus is associated with a dermal disorder, a psychological disorder, a mental disorder, a nerve disorder, or a systemic disorder.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61K 9/00 - Medicinal preparations characterised by special physical form

17.

TREATMENT OF PRURITIC CONDITIONS MEDIATED THROUGH HISTAMINE H-4 RECEPTORS

      
Document Number 02919078
Status In Force
Filing Date 2014-07-31
Open to Public Date 2015-02-12
Grant Date 2021-08-10
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of histamine H-4 - related dermal disorders, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases for the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61P 17/04 - Antipruritics

18.

Methods of treatment of histamine H-4 receptor-related pruritus

      
Application Number 13960114
Grant Number 09138431
Status In Force
Filing Date 2013-08-06
First Publication Date 2015-02-12
Grant Date 2015-09-22
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of histamine H-4—related pruritus, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases of the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

19.

METHODS OF TREATING PRURITIC CONDITIONS MEDIATED THROUGH HISTAMINE H-4 RECEPTORS

      
Application Number US2014049173
Publication Number 2015/020878
Status In Force
Filing Date 2014-07-31
Publication Date 2015-02-12
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of histamine H-4 - related dermal disorders, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases for the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61P 17/04 - Antipruritics

20.

MEDICINAL TREATMENT OF CHRONIC DERMAL INFLAMMATORY DISEASES WITH NORKETOTIFEN

      
Document Number 02886194
Status In Force
Filing Date 2013-10-29
Open to Public Date 2014-05-08
Grant Date 2018-01-09
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of chronic dermal disorders, such as for example atopic dermatitis or psoriasis, in human patients, by orally or topically administering a therapeutically effective amount of RS-norketotifen. Therapeutic antimicrobial activity of RS-norketotifen against Malassezia sp. and Staphylococcus aureus are also described.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
  • A61P 17/00 - Drugs for dermatological disorders
  • A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P 31/04 - Antibacterial agents
  • A61P 31/10 - Antimycotics
  • C07D 409/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

21.

TREATMENT OF CHRONIC DERMAL INFLAMMATORY WITH NORKETOTIFEN

      
Application Number US2013067177
Publication Number 2014/070696
Status In Force
Filing Date 2013-10-29
Publication Date 2014-05-08
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of chronic dermal disorders, such as for example atopic dermatitis or psoriasis, in human patients, by orally or topically administering a therapeutically effective amount of RS-norketotifen. Therapeutic antimicrobial activity of RS-norketotifen against Malassezia sp. and Staphylococcus aureus are also described.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
  • C07D 409/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

22.

MEDICINAL TREATMENT OF DERMAL DISEASES IN COMPANION ANIMALS WITH NORKETOTIFEN

      
Application Number US2013065847
Publication Number 2014/066212
Status In Force
Filing Date 2013-10-21
Publication Date 2014-05-01
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of dermal disorders, such as for example atopic dermatitis, in dogs, by administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against Malassezia sp. is also described.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

23.

Medicinal treatment of dermal diseases in companion animals

      
Application Number 14025302
Grant Number 08778971
Status In Force
Filing Date 2013-09-12
First Publication Date 2014-04-24
Grant Date 2014-07-15
Owner Bridge Pharma, Inc. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent B.

Abstract

Malassezia sp. is described.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

24.

Medicinal treatment of dermal diseases in dogs

      
Application Number 13739090
Grant Number 08557846
Status In Force
Filing Date 2013-01-11
First Publication Date 2013-10-15
Grant Date 2013-10-15
Owner Bridge Pharma, Inc. (USA)
Inventor
  • Aberg, A. K. Gunnar
  • Ciofalo, Vincent B.

Abstract

The methods disclosed herein relate to the treatment of dermal disorders, such as for example atopic dermatitis, in dogs, by administering a therapeutically effective amount of racemic norketotifen. Co-administrations with steroids or immunosuppressant drugs are described.

IPC Classes  ?

  • A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

25.

TREATING XEROPHTHALMIA WITH COMPOUNDS INCREASING MEIBOMIAN GLAND SECRETION

      
Application Number US2010058317
Publication Number 2011/068786
Status In Force
Filing Date 2010-11-30
Publication Date 2011-06-09
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Ciofalo, Vincent, B.

Abstract

Methods for the treatment of patients suffering from dry eyes, by using adrenergic beta-receptor agonists, particularly salbutamol and in particular the optically pure or substantially pure R-enantiomer thereof. The embodiments disclosed herein include methods of increasing the Meibomian lipid secretion and thereby reducing or eliminating xerophthalmia symptoms by the administration of formulations containing therapeutically effective amounts of an adrenergic beta-receptor agonist to said patients. In particular, certain embodiments disclosed herein concern compositions that contain R-salbutamol as the active beta-receptor stimulating ingredient. In certain embodiments, the formulations are administered to the ocular surface of the eye and/or to the eyelid (the underside of the eyelid and/or the top of the eyelid) of a patient in need thereof.

IPC Classes  ?

  • A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
  • A61P 27/02 - Ophthalmic agents
  • A61P 27/00 - Drugs for disorders of the senses

26.

OCULAR FORMULATIONS OF NORKETOTIFEN

      
Application Number US2009065252
Publication Number 2010/059894
Status In Force
Filing Date 2009-11-20
Publication Date 2010-05-27
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K. Gunnar
  • Johnson, Keith

Abstract

Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.

IPC Classes  ?

  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

27.

TREATING XEROPHTHALMIA WITH NORKETOTIFEN

      
Application Number US2008014056
Publication Number 2010/047681
Status In Force
Filing Date 2008-12-24
Publication Date 2010-04-29
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A.K., Gunnar
  • Johnson, Keith

Abstract

Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.

IPC Classes  ?

  • A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom

28.

USE OF RR/SR-RACTOPAMINE

      
Application Number US2008009428
Publication Number 2009/073051
Status In Force
Filing Date 2008-08-06
Publication Date 2009-06-11
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A., K., Gunnar
  • Reuter, Karl
  • Meier, Viktor
  • Stolz, Florian
  • Gogritchiani, Eliso

Abstract

A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR- ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.

IPC Classes  ?

  • A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine

29.

SYNERGISMS BETWEEN REPARTITIONING AND IMMUNOMODULATING COMPOUNDS

      
Application Number US2008009447
Publication Number 2009/020620
Status In Force
Filing Date 2008-08-06
Publication Date 2009-02-12
Owner BRIDGE PHARMA, INC. (USA)
Inventor Aberg, A.K., Gunnar

Abstract

Combination therapies of adrenergic beta-receptor agonists and beta-glucans are described.

IPC Classes  ?

  • A01N 33/02 - AminesQuaternary ammonium compounds
  • A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone

30.

DERMAL COMPOSITIONS OF SUBSTITUTED AMIDES AND THE USE THEREOF AS MEDICATION FOR PAIN AND PRURITUS

      
Application Number US2008000425
Publication Number 2008/088756
Status In Force
Filing Date 2008-01-11
Publication Date 2008-07-24
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, A., K., Gunnar
  • Johnson, Keith, A.

Abstract

Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain by the topically administration of these compounds are also provided.

IPC Classes  ?

  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
  • A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

31.

DERMAL ANESTHETIC COMPOUNDS

      
Application Number US2007016480
Publication Number 2008/011161
Status In Force
Filing Date 2007-07-20
Publication Date 2008-01-24
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Wright, George, E.
  • Aberg, A.K., Gunnar

Abstract

The present invention relates to new tetralin compounds, the methods of preparing said tetralin compounds, the method of using said tetralin compounds as local anesthetics and dermal anesthetics, said compounds having particularly valuable properties as dermal and topical anesthetics in mammals, including man, as well as compositions containing said compounds.

IPC Classes  ?

  • C07D 211/56 - Nitrogen atoms
  • A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings

32.

INDANYLAMINES AND THEIR USE FOR LOCAL ANESTHESIA AND CHRONIC PAIN

      
Application Number US2006037070
Publication Number 2007/038325
Status In Force
Filing Date 2006-09-22
Publication Date 2007-04-05
Owner BRIDGE PHARMA, INC. (USA)
Inventor
  • Aberg, Gunnar, A., K.
  • Johnson, Keith

Abstract

Dermal and mucosal formulations of 2-[2-(N-phenyl-N-2-indanyl) aminoethyl] piperidine, characterized by rapid dermal and mucosal absorption and long duration of therapeutic activity are provided. Also provided are solutions of 2-[2-(N-phenyl-N-2-indanyl) aminoethyl] piperidine for injection, characterized by short onset time and long duration of activity. Formulations containing both 2-[2-(N-phenyl-N-2-indanyl) aminoethyl] piperidine and capsaicin are also provided.

IPC Classes  ?

  • A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame